Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 15/20 | 0.64 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7410812 | 0.80 | HSD11B1 (0.52) | HSD11B1MEN1KMT2AALDH1A1LMNA | |
| SCHEMBL5089055 | 0.79 | HSD11B1 (0.58) | HSD11B1MEN1KMT2AALDH1A1LMNA | |
| SCHEMBL348724 | 0.79 | HSD11B1 (1.00) | HSD11B1MEN1KMT2AALDH1A1 | |
| SCHEMBL350439 | 0.73 | HSD11B1 (1.00) | HSD11B1MEN1KMT2AALDH1A1LMNA | |
| SCHEMBL351050 | 0.73 | HSD11B1 (1.00) | HSD11B1MEN1KMT2AALDH1A1LMNA | |
| SCHEMBL17804163 | 0.72 | HSD11B1 (0.66) | HSD11B1MEN1KMT2AALDH1A1LMNA | |
| SCHEMBL3139523 | 0.72 | HSD11B1 (0.71) | HSD11B1MEN1KMT2AALDH1A1LMNA | |
| SCHEMBL3129900 | 0.72 | HSD11B1 (1.00) | HSD11B1MEN1KMT2AALDH1A1LMNA | |
| SCHEMBL5643459 | 0.71 | HSD11B1 (0.71) | HSD11B1MEN1KMT2AALDH1A1LMNA | |
| SCHEMBL5094333 | 0.71 | HSD11B1 (0.67) | HSD11B1MEN1KMT2AALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7425641-B2 | Carboxylic acid amides, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2008-09-16 | — | — | US | disclosed |
| US-20050065346-A1 | Carboxylic acid amides, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2005-03-24 | — | — | US | disclosed |
| EP-1206446-B1 | CARBOXYLIC ACID AMIDES, THEIR PRODUCTION AND THEIR USE AS DRUGS | BOEHRINGER INGELHEIM PHARMA (DE) | 2004-05-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050065346-A1 | Carboxylic acid amides, the preparation thereof and their use as pharmaceutical compositions | F12, F11, F2 | HSD11B1 1366/4885MEN1 888/4885KMT2A 3156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.